Celgene Corporation (CELG): Expanding Labels to Expand Margins

Page 1 of 2

In an industry where buyouts are commonplace and small-cap biotechs burn through cash rapidly, optimizing operating cash flow can be essential to a company’s financial health. Is cash being applied efficiently to maximize sales while minimizing the cost of R&D? Perhaps the most powerful way to maximize revenue potential and minimize cost is through label expansion.

Companies with nascent revenue streams must appropriately limit costs while fostering newfound revenue. By selectively searching for new indications, or approved uses, for drugs, pharma can bypass the costly process of novel drug discovery, enhance manufacturing and commercialization margins by extending the utility of fixed costs, and grow revenue by exposing the drug to patients in new markets. The industry is teeming with drugs for which companies have cut margins by expanding drug labels.

Below we will look at a few exemplary cases in which label expansion has improved the growth prospects of drugmakers in two sectors.

Oncology

The oncology space provides biotech or pharmaceutical companies with a great opportunity to expand labels. FDA approval for cancer drugs can be specific to cancer type and treatment regimen (primary treatment vs secondary or co-treatment). Yet the diversity of cancer types with common molecular underpinnings makes some drugs widely applicable, providing an opportunity to expand the market without the costs of complete drug development.

Celgene Corporation (NASDAQ:CELG)Celgene Corporation (NASDAQ:CELG) is a wonderful example of a company pursuing label expansion. Celgene has six approved drugs on the market for treatment of cancer. Of those six, five of them are in additional clinical trials or are under FDA review for use in new indications. Eleven Phase III trials are currently listed on Celgene’s website, investigating the use of approved drugs in additional indications. Contrast this with the four Phase III trials underway for new drug candidates, and it is clear that Celgene’s short-term revenue growth will come from label expansion, providing ample capital to be invested in preclinical drug discovery.

Celgene Corporation (NASDAQ:CELG)’s leading revenue generator, Revlimid, is currently approved to treat two types of blood cancer – including as a secondary treatment multiple myeloma and relapsing or treatment-resistant mantle cell lymphoma – and for diseases of the bone marrow called myelodysplastic syndromes. Revlimid brought in $3.7 billion in 2012, yet Celgene continues to exploit the drug’s widespread utility with clinical trials for twelve additional indications (eight are in Phase III). The recent success of Revlimid as a primary treatment for multiple myeloma in a Phase III trial suggests that this strategy might pay off, sending the stock to new all-time highs.

Celgene Corporation (NASDAQ:CELG)’s multiple myeloma competitor Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is another example of a company using label expansion to limit costs. While annual operating expenses did increase from 2011 to 2012, Onyx’s 10-K suggests that this is in large part due to costs incurred from label expansion of its only wholly owned drug, Kyprolis. Kyprolis was approved in 2013 as a third-line treatment for multiple myeloma. It is now in three additional Phase 3 trials for other multiple myeloma treatment courses. Amgen, Inc. (NASDAQ:AMGN)‘s rumored $10 billion acquisition offer to Onyx suggests that they, too, appreciate Onyx’ commitment to label expansion. Onyx has rebuffed that offer, but it will certainly be interesting to see which suitor also values Onyx’ approach to drug development.

Autoimmune Disease

Like cancer, autoimmune disorders come in many varieties and flavors, yet often times the underlying molecular causes are similar enough that one drug can treat myriad illnesses. This is particularly the case for diseases of chronic inflammation.

A specific chemical pathway in most cells called the Tumor Necrosis Factor, or TNF, pathway can be activated by the immune system to cause ‘programmed’ cell death. In healthy subjects, this pathway helps to keep potentially dangerous tumor cells from spreading. In other cases, hyperactivity of the pathway can cause inflammation and tissue damage, among other things. This pathway can therefore be blocked to treat diverse ailments associated with auto-immune diseases and inflammation. Four companies have cashed in big time with blockbuster drugs targeting TNF signaling.

AbbVie’s Humira, Amgen, Inc. (NASDAQ:AMGN)‘s and Pfizer Inc. (NYSE:PFE)’s Enbrel, and Johnson & Johnson (NYSE:JNJ)’s Remicade combined for $23 billion in 2012. Treating diseases as diverse as rheumatoid arthritis, to Crohn’s Disease, to psoriasis, these drugs have thrived in large part because of their expansive labels. AbbVie is currently pursuing five additional indications (in the US) for further label expansion of Humira – currently the best selling drug in the world.

Drug 2012 Revenue
Approved Indications*
Humira $9.27 billion 7
Enbrel $7.97 billion 5
Remicade $6.14 billion 8

Source: Full Prescribing Information on drug website. Only in US.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!